A Phase II, Multicentre, Randomised, Placebo-controlled, Doublemasked Trial of RP101 Ophthalmic Formulation Versus Vehicle in Post-menopausal Women With Moderate to Severe Dry Eye Syndrome
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2019
At a glance
- Drugs RP-101-Redwood Pharma (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Redwood Pharma
- 04 Feb 2019 According to a Redwood Pharma media release, first patient has been treated in the trial. Assuming the trial proceeds according to plan, results of the trial should be published no later than Q1 2020.
- 04 Feb 2019 Status changed from not yet recruiting to recruiting, according to a Redwood Pharma media release.
- 28 Jan 2019 Status changed from planning to not yet recruiting.